Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
This research aims to study people who have had their first episode of symptomatic deep vein thrombosis DVT in their lower limbs to understand the risk and severity of post-thrombotic syndrome PTS, the most common long-term complication of DVT. The study focuses on evaluating how the amount of thrombosis blood clot burden measured by the Venous Volumetric Index VVI on ultrasound relates to the development and severity of PTS assessed by the Villalta scale over 6 months. Participants will be followed at multiple times around 1 week, 1 month, 3 months, and 6 months after diagnosis. At each visit, doctors will assess symptoms and signs to calculate the Villalta score and perform venous ultrasounds to measure thrombosis burden using the VVI. Blood samples will be collected at several visits to study inflammation, coagulation, and clot breakdown factors. Quality of life questionnaires will also be completed at 3 and 6 months. During the study, symptom assessments, ultrasound exams, blood tests, and questionnaires will help researchers understand how the thrombosis burden at baseline and over time relates to the occurrence and severity of PTS. The study ends with the 6-month visit. Researchers will monitor the presence of moderate to severe PTS and changes in clot burden to identify important prognostic factors that may guide future prevention and treatment strategies.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the nutritional effects of a new hydrolyzed rice protein-based infant formula compared to a standard cows milk protein formula in healthy term infants. The study aims to determine if the daily weight gain of infants fed the experimental rice formula for the first four months is not worse than that of infants fed the standard formula. This trial is randomized and quadruple-masked, involving healthy singleton infants born at term with adequate birth weight. Participants are fed exclusively with either the experimental rice-based formula or the control cows milk formula starting from around 7 to 13 days old until they reach 120 days of age. Parents record any deviations from exclusive feeding, including intake of other foods or formulas. The study includes scheduled visits at postnatal days 20, 30, 60, 90, and 120 to monitor feeding, digestive tolerance, behavior, and formula acceptance. During the study, parents also assess their infants quality of life at enrollment and at days 60 and 120. Researchers measure daily weight gain as the primary outcome. The trial includes regular monitoring of feeding patterns and infant well-being through parent diaries and assessments over the four months. Participation lasts from enrollment until the infant reaches 120 days old, with ongoing data collection at specified intervals.
Actively Recruiting
Researchers are investigating risk markers for sudden cardiac death SCD in patients who have ischemic heart disease with moderately impaired left ventricular ejection fraction LVEF between 35% and 50%. Despite advances in treatment after myocardial infarction, the risk of sudden death remains a major concern, especially in those with complications such as ventricular arrhythmias and myocardial scarring. Current risk assessment mainly relies on LVEF below 35%, which is not sufficient for patients with moderately reduced LVEF. This study aims to develop a predictive risk score for sudden death in this group. Participants who had a STEMI heart attack at least 40 days prior with LVEF between 35% and 50% will undergo various examinations including cardiac MRI, echocardiography, ECG, Holter monitoring, blood and genetic sampling, and implantation of an implantable loop recorder ILR device for continuous heart rhythm monitoring with remote monitoring. These assessments will provide data to create a risk prediction score. Patients will be followed clinically and by remote monitoring for up to 60 months. Throughout the study, participants will have annual cardiology visits including clinical exams, ECG, echocardiography, and blood tests. The implantable loop recorder will continuously monitor heart rhythms to detect arrhythmias. Researchers will track occurrences of sudden cardiac death, malignant ventricular arrhythmias, and other related events to evaluate potential predictive markers. The study includes safety monitoring and prohibits certain antiarrhythmic drugs except beta-blockers during follow-up.
Actively Recruiting
Calciphylaxis, also called uremic calcifying arteriolopathy UCA, is a rare condition causing painful skin lesions due to small blood vessel calcification and clotting. This disease mainly affects patients with end-stage renal disease ESRD who require hemodialysis. Researchers are evaluating the safety and effectiveness of adding rheopheresis, a special blood filtration treatment, to the standard care for calciphylaxis in these patients through a prospective randomized controlled trial. In this study, participants will be randomly assigned to one of two groups. The experimental group will receive rheopheresis in addition to standard care, involving an induction phase of 3 sessions in the first week followed by 2 sessions weekly for 3 weeks, then a maintenance phase with 1 session per week up to week 11. The comparator group will receive sham-apheresis sessions on the same schedule, which mimics the procedure without actual filtration. Rheopheresis uses a machine to remove certain high molecular weight proteins from plasma to help treat microcirculation problems. Participants will be followed for 12 weeks during treatment with regular assessments of wound healing, pain levels, quality of life, antibiotic usage, hospital discharge days, survival, and inflammatory protein changes. The primary outcome is the percentage of patients achieving complete healing of calciphylaxis lesions after 12 weeks. Secondary outcomes include partial healing, new lesion occurrence, pain and analgesic use, and overall survival at 12 weeks and one year. Safety and efficacy data will help determine the added value of rheopheresis in calciphylaxis care.
Actively Recruiting
Sepsis is a serious condition caused by an uncontrolled response to infection that leads to dangerous organ failure. Septic shock, the most severe form, involves low blood pressure and poor tissue oxygenation. Early treatment to improve blood flow and oxygen delivery is vital to prevent further organ damage and death. This trial compares two methods for guiding early treatment in adults with septic shock one using the difference in carbon dioxide pressure between venous and arterial blood CO2 gap and the other based on blood lactate levels, which are commonly used but not direct markers of tissue oxygen delivery. Participants will be randomly assigned to one of two groups. The first group will receive treatment guided by keeping the CO2 gap below 6 mmHg using a step-by-step approach with blood samples taken every 2 to 4 hours. The second group will have treatment aimed at reducing lactate levels by 20% every 2 to 4 hours, following current sepsis guidelines. Treatments include standard care with adjustments based on these measurements, such as use of medications like dobutamine or blood transfusions. The study takes place in intensive care units and monitors patients closely during their early resuscitation phase. Participants will be observed daily for 28 days after starting the study to assess survival and organ function. Researchers will collect blood samples regularly and evaluate clinical scores related to organ health. The main outcome is death from any cause within 28 days. Secondary outcomes include various measures of treatment effectiveness and safety. The study will last until the end of 2027, with careful monitoring and data collection to determine which resuscitation strategy may improve survival in septic shock patients.